## EXHIBIT 33

```
Page 251
 1
                       SUPERIOR COURT OF NEW JERSEY
                      LAW DIVISION - MIDDLESEX COUNTY
                      DOCKET NO. MID-L-003809-18AS
 2.
 3
 4
      KAYME A. CLARK and
      DUSTIN W. CLARK,
 5
                                         104 HEARING
                                    )
 6
                   Plaintiffs,
                                        TRANSCRIPT OF
                                   )
                                         PROCEEDINGS
 7
            v.
                                        (VOLUME II)
 8
      JOHNSON & JOHNSON, et al.,
 9
      et al.,
10
                   Defendants.
11
12
                   Place: Middlesex County Courthouse
                           56 Paterson Street
13
                           New Brunswick, New Jersey 08903
14
                   Date: May 30, 2024
15
                           9:01 a.m.
16
17
      B E F O R E:
18
            HONORABLE ANA C. VISCOMI, J.S.C.
19
20
21
                   ANDREA F. NOCKS, CCR, CRR
                   PRIORITY ONE
22
                   290 West Mount Pleasant Avenue
                   Livingston, New Jersey 07039
                    (718) 983-1234
23
                   E-mail: plsteno@veritext.com
24
25
      JOB NO.: 6725593
```

	Page 252			Page 254
1	APPEARANCES:	1	EXHIBITS	Ü
2	DEAN OMAR BRANHAM SHIRLEY LLP	2		ID
3	BY: BENJAMIN BRALY, ESQ. 302 North Market Street	3	P-3 ISO table 345	110
	Suite 300	Ī.	F-5 150 table 545	
4	Dallas, Texas 75202	4	D.C. A. II' . WIII' D. O.C.	
5	Attorneys for Plaintiffs	5	P-6 Appendices to White Paper 266	5
6		6		
7		7	P-20 Deer, Howie and Zussman	
8	KING & SPALDING	8	page from textbook 257	
9	BY: MORTON D. DUBIN II, ESQ. KEVIN HYNES, ESQ.	9		
	1185 Avenue of the Americas	10	P-31 Decades of Evidence chart 264	1
10	34th Floor	11	201	
11	New York, New York 10036 -AND-	12		
11	McCARTER & ENGLISH			
12	BY: JOHN C. GARDE, ESQ.	13		
12	Four Gateway Center	14		
13	100 Mulberry Street Newark, New Jersey 07102	15		
14	Attorneys for Defendant,	16		
	Johnson & Johnson	17		
15 16		18		
17	ALSO PRESENT: MARK BIBRO, ESQ.	19		
	EARLY, LUCARELLI,	20		
18	SWEENEY & MEISENKOTHEN	21		
20				
21		22		
22		23		
23 24		24		
25		25		
	Page 253			Page 255
1	Page 253 INDEX	1	THE COURT: Good morning, ever	_
1 2	_			yone.
	_	2	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here	yone. e with
3	INDEX	2 3	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. We	ryone. e with illiam
2 3 4	INDEX WITNESSES DIRECT CROSS REDIRECT RECROSS	2 3 4	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus	ryone. e with illiam tin Clark
2 3 4 5	INDEX	2 3 4 5	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3	ryone. e with illiam tin Clark
2 3 4 5 6	INDEX WITNESSES DIRECT CROSS REDIRECT RECROSS WILLIAM EDWARD LONGO	2 3 4 5 6	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on	ryone. e with illiam tin Clark
2 3 4 5 6 7	INDEX  WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY:	2 3 4 5 6 7	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3  May I have appearances, please, on behalf of plaintiff.	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalf	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8	INDEX  WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY:	2 3 4 5 6 7 8 9	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. William Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8 9	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. William Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8 9 10	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. W. Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from	ryone. e with illiam tin Clark 3809-18.
2 3 4 5 6 7 8 9 10 11 12 13	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.	ryone. e with illiam tin Clark 8809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you	ryone. e with illiam tin Clark 8809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt he Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.	ryone. e with illiam stin Clark 3809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalthe Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the	ryone. e with illiam stin Clark 3809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.	ryone. e with illiam stin Clark 3809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.	ryone. e with illiam stin Clark 3809-18. alf of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.	ryone. e with illiam stin Clark 3809-18. alf of om Early
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.	ryone. e with illiam stin Clark 3809-18. alf of om Early
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.	ryone. e with illiam stin Clark 3809-18. alf of  Early  e,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.  MR. GARDE: If Your Honor please.	ryone. e with illiam stin Clark 3809-18. alf of  Early  e, son
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.  MR. GARDE: If Your Honor please.  John Garde on behalf of the Johnson & Johns defendants. With me is Mr. Morton Dubin ar	ryone. e with illiam stin Clark 3809-18. alf of  Early  e, son
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behalt the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.  MR. GARDE: If Your Honor please.  John Garde on behalf of the Johnson & Johns defendants. With me is Mr. Morton Dubin ar Mr. Kevin Hynes of King & Spalding.	ryone. e with illiam stin Clark 3809-18. alf of  Early  e, son
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	WITNESSES DIRECT CROSS REDIRECT RECROSS  WILLIAM EDWARD LONGO  EXAMINATION BY: MR. BRALY 256 342, 353	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	THE COURT: Good morning, ever My name is Judge Ana Viscomi. We are here regard to the continued 104 hearing of Dr. Williams Longo in the matter of Kayme Clark and Dus versus Johnson & Johnson, Docket Number 3 May I have appearances, please, on behalf of plaintiff.  MR. BRALY: Your Honor, on behat the Clark family I'm here, Benjamin Braly.  THE COURT: Thank you.  Further on behalf of the plaintiff?  MR. BRALY: Mr. Bibro is here from the Early firm.  THE COURT: I'm sorry. Could you state your name again, please.  MR. BIBRO: Mark Bibro from the firm.  THE COURT: Thank you.  And for the defendants.  MR. GARDE: If Your Honor please.  John Garde on behalf of the Johnson & Johns defendants. With me is Mr. Morton Dubin ar	ryone. e with illiam stin Clark 3809-18. alf of om Early e, son

Page 276

1 actually chrysotile, right; you're aware that he has2 offered that opinion, correct?

- 3 A. I would say yes, he has offered that 4 opinion. And he has done the most research on 5 polarized light microscopy dispersion staining, but 6 I don't believe he's done any research on the 7 chrysotile in cosmetic talcs.
- 8 Q. Okay. And not only has he said,
  9 based on being the most experienced person in
  10 research in this type of analysis that what you are
  11 calling chrysotile is actually talc, he has said you
  12 are not properly following PLM dispersion staining
  13 analysis methodology, correct?
- 14 A. He has stated that.
- 15 Q. And, for example, we had one example 16 of that during your testimony yesterday, for 17 example, you put a table up that was from one of his 18 publications, and we can just call up slide 161 19 first.
- And so, this is a PowerPoint actually
  from Dr. Su but the table inside this is what you
  were referring to yesterday when you were talking
- 23 about what the acceptable ranges of refractive
- 24 indices are for chrysotile, right?
- 25 A. Correct.

Page 277

1 Q. And not only has he -- let's just 2 look at an excerpt from his report here. We could 3 go to slide 160.

And what he says is, "I have created and published procedures for reference tables that help analysts measure RI values of the six regulated asbestos minerals, including chrysotile. MAS relies

8 upon my procedure and tables as part of its PLM 9 analysis of Johnson's Baby Powder. However,

10 Dr. Longo completely misunderstood my reference

11 table and claimed that the RI range of my chrysotile

12 table represents the chrysotile's minimum and

13 maximum RI values. This is not true."

14 And you're aware he said that, right?

15 A. I am aware.

Q. So, the author of the method that you

17 claim to be following is saying that you are

18 misinterpreting the method, right?

19 A. He says we're misinterpreting the 20 method, however, if you look at some of the

21 reference chrysotile ranges, you have ranges of

22 chrysotile that are both in the area that we find

 $23\,$  and also in the area that is outside what Dr. Su

24 says is appropriate. And if you take those, such as

25 what's found in EPA, what's found in others, and if

Page 278

1 you take those and go on his chart, they do match

2 the appropriate refractive indice. So, my

3 intuition there is he has come up with a range that

4 is not -- covers all chrysotile.

Q. Okay. But no question that you put a
slide up there yesterday in your examination from
his method, and he has told you you are wrong about

8 what this table means, and you still use it, right?

9 A. Of course we still use it because the 10 range of what we're finding in something like 11 refractive indices, you know, there's a 1.567 in

12 EPA. According to Dr. Su, that would be out of the

13 range and you can't use his table. That 1.567

14 matches the refractive indices perfectly.

And there's another one, like we just looked at, is 1.538. According to Dr. Su, that would be out of the range that you would call chrysotile. So, I can't quibble with that's what he says, that's what he thinks his chart is, but it doesn't cover all the chrysotile minerals that are out of the typical range.

22 Q. And we're going to be talking a 23 little bit more about your failure to verify but --24 right -- the whole reason we're even having this 25 conversation, we're looking at is this yellow,

Page 279

1 bright yellow, is this golden yellow, is it purple,

2 the whole reason we're having this conversation at3 all is because we're talking about PLM dispersion

4 analysis, right, which is based on color, correct?

5 A. That is correct.

6 Q. But if you had even once decided to 7 use TEM to verify your findings, you could look at 8 what you're calling chrysotile, you could get direct

9 information about crystal structure and chemistry

10 and know fairly simply is it chrysotile or is it

11 talc, right?

12 A. Right.

13 Q. Without talking about colors at all?

14 A. Right, and we have done that. We

15 have now taken samples that we have said is16 chrysotile in it with the same ranges we're talking

17 about and the ranges that Dr. Su says is out of his

18 table and have verified that it has chrysotile.

19 Q. No, what I'm saying is you could look 20 at Johnson & Johnson with a TEM, take your

21 concentration method, if you think concentration --

22 you could take the concentration, what you got, look 23 at it under a TEM analysis and find what you say is

24 chrysotile. And if you found it with TEM and you

25 had chemistry information and crystal structure

**Document 33015-8** PageID: 222176

Page 280

- 1 information, we wouldn't even be having to debate
- 2 whether you are calling particles the wrong color;
- 3 we would have hard data, right?
- 4 Well, we would have hard data but
- 5 what you're saying is not very fair.
- We are analyzing samples and showing
- 7 chrysotile in it with the same methodology, the same
- 8 everything we're doing and, actually, one of the
- Avon samples is a Vermont sample.
- 10 So, no, have we gotten to J&J yet?
- 11 You're going to have to be patient for that. So, I
- 12 look at it as we have now verified it a number of
- 13 ways. We have verified it by TEM in Avon samples.
- 14 We have verified it using the SG-210 as a standard
- 15 because it has the exact same -- not the exact same
- 16 but the same range of refractive indices and we're
- 17 not the only one finding chrysotile by TEM in these
- 18 cosmetic talcs, as we just saw. So that's also
- 19 verified.
- 20 Q. You say you haven't got into it yet.
- 21 But we looked and when you -- you started claiming
- 22 there was chrysotile and Johnson & Johnson finding
- 23 it back in 2020, right?
- 24 A. With PLM, that's correct.
- 25 So, at minimum, even if we ignore the Q.

Page 282

Page 283

- 1 workload that we're not doing any work on it, we're
- 2 doing the best we can.
- 3 Q. Let's break what you just said down
- 4 into two pieces.
- 5 First, you said we're not a research
- 6 institution, right, we are not a research
- 7 institution so why should we go and do this
- 8 additional work?
- 9 No. No, you mis --A.
- Let me finish my question. 10 Q.
  - A. Okay. Sorry.
- 12 You are currently charging \$50,000 Q.
- 13 retainers every time you are retained in a cosmetic
- 14 talc case, right?
- 15 A. Since May first of this year, that's
- 16 correct.
- 17 Q. And how many cosmetic talc cases
- 18 would you say that you're currently being retained
- 19 in?

21

24

1

11

- 20 A. Four or five.
  - Q. Okay. Over this entire -- let's say
- 22 this year?
- 23 A. Maybe six or seven.
  - Q. Currently, or how about last year,
- 25 how many cases?

Page 281

- 1 fact that you began this work overall in 2016,
- 2 you've had four years, four years to look at
- 3 Johnson & Johnson talc with a TEM microscope and
- 4 prove that what you're calling chrysotile is
- 5 chrysotile with chemistry information and crystal
- 6 structure information, at least four years, right?
- 7 A. It's been four years but that's
- 8 absolutely unfair. We're a commercial lab. We're
- 9 not a research institute. Yes, if I -- if I was a
- 10 research institute or I was a university, I could
- 11 put a couple Ph.D. students on this where they would
- 12 be working on it full-time. We don't get funding
- 13 for that. So, it takes us a long time to go through

- 15 was not in a way from the methodology where we had 15 heavy liquid density separation method on it, CSM,
- 16 to work on it. Unlike the amphibole one, where it 17 had been published and there's a method for it, you
- 18 could go right in and start finding amphiboles. The
- 19 chrysotile one just had this protocol from Colorado
- 20 School of Mines where they're finding chrysotile by
- 21 PLM and did not do TEM on it. But we had to figure
- 22 out how to make the concentration method the most,
- 23 you know, efficient of extracting out the talc in
- 24 the chrysotile. That was not an easy thing.
- 25 You know, we may go days because of

- Last year, I don't know. We didn't
- 2 start charging this retainer to help us in the
- 3 research last year.
- But you're not making enough money
- 5 where you could afford to have somebody, instead of
- 6 doing one PLM analysis, switch them over and look at
- 7 a TEM analysis to verify; that's what you're saying?
- No, I'm not saying that. It's -- we
- 9 have -- we have samples that are due. Now we've
- 10 hired additional people and since we have now been
- 11 able to fund this, now we've started looking at it
- 12 by TEM. Now, the reason we did the TEM the way we
- 13 did is because another scientist by the name of Mark
- 14 that. And the CSM method was not in, you know -- it 14 Bailey took three Avon -- three Avon samples, used a

  - 16 but he made some tweaks on it that we're now using,
  - 17 and we wanted to do the first ones to verify what
  - 18 that scientist found. So, now we have verification
  - 19 from two different labs and, yes, we're going to
  - 20 expand in it, and, yes, we've been hiring some
  - 21 people now that we've got the \$50,000 retainer. We 22 got two new PLM analysts and we're looking for some
  - 23 additional people to help move this along, but
  - 24 before we got the retainers, we didn't have the
  - 25 money to hire people.

**Document 33015-8** PageID: 222177

Page 284

- Q. Let's look at the second thing that
- 2 you said. You said, well, we were still developing
- 3 the CSM method. You told Congress back in 2020 that
- 4 you had already cracked the code on a method to
- 5 concentrate for chrysotile and find chrysotile,
- 6 right?

1

- 7 A. That's untrue.
- 8 Q. It was untrue that you cracked the
- 9 code?
- 10 That I told Congress that. I told
- 11 Congress that we didn't have a method yet for
- 12 chrysotile, it was only amphiboles.
- We'll look at that. But your CSM
- 14 method was sufficiently developed back in 2020 that
- 15 you were using it for PLM, right?
- Again, you're correct but you're
- 17 being unfair. We were using it for PLM but we were
- 18 finding that we were getting less in the
- 19 concentration method than we were with just looking
- 20 at it. We were finding that the chrysotile was
- 21 ending up in the pellet, which makes absolutely no
- 22 sense. So, we had to solve that riddle.
- But if you still had to solve the CSM
- 24 problem, if the CSM method wasn't reliable enough to
- 25 use for TEM, then it wouldn't have been reliable
- Page 285
- 1 enough to use for PLM either?
- That is so wrong. The PLM method was
- 3 showing it was there. We were getting positive
- 4 chrysotile but we weren't getting the full amount
- 5 that should have been in there. That's why we had
- 6 to go to -- we had to go to using the SG-210, one,
- 7 to figure out why is it going into pellet. Well, it
- 8 took time to do that. And you guys know in your
- 9 office, you know, somebody comes in and says, you
- 10 know, I need two more, you know, motions to strike
- 11 and if you don't have enough people, how do you do
- 12 it?
- 13 So, when you were back testifying,
- 14 when you started testifying about your PLM work
- 15 using this CSM concentration method, did you tell
- 16 juries that, "Hey, wait, I'm presenting this about
- 17 my concentration chrysotile stuff by PLM but you
- 18 shouldn't be paying attention to this because the
- 19 method's really not worked out?" Is that what you
- 20 said about your method when you were testifying
- 21 about it?
- 22 Of course not. What I was telling A.
- 23 the juries is that we're finding chrysotile, it was
- 24 positive for chrysotile. It doesn't -- it may not
- 25 be the right amount but it's absolutely positive for

- Page 286 1 chrysotile by PLM. That's what I was telling the
  - 2 jury. I wasn't telling them that we still have
  - 3 things to do on it but before we got the TEM, I
  - 4 wanted it to be the message that we would publish
  - 5 and say this is what you do. We had to solve all
  - 6 these little issues. They weren't little issues,
  - 7 they were -- they were scratch head issues.
  - 8 Q. Okay.
  - 9 So two different things. A.
  - 10 Q. So, let's move back -- I'm sorry.
  - 11 Are you done?
  - 12 A. No.
  - 13 Q. Okay.
  - 14 If it is positive by PLM, that means A.
  - 15 there's chrysotile in it. And what we were -- and
  - 16 getting the exact amounts and getting the most
  - 17 efficient extraction so that we could use it so we
  - 18 knew in TEM that if it's there, we could detect.
  - 19 That was the whole issue.
  - 20 Let's go back and reorient about what
  - 21 else you've been talking. Let's just go to the
  - 22 orientation slide, slide 1. A lot of people
  - 23 couldn't see slide 1.
  - 24 So, we sort of talked a little bit
  - 25 about these first two things already but, as I said,
- Page 287 1 when we move from TEM which gives you just printouts
  - 2 of data, when we start to change to a PLM dispersion
  - 3 staining analysis, I think you actually said that
  - 4 even people who use PLM to identify minerals in
  - 5 practice usually don't do it this way where you have
  - 6 to depend on color of the particle, the
  - 7 birefringence; you said they usually use Michel-Levy
  - 8 charts, right?
  - 9 A. Correct.
  - 10 So, you selected not just a PLM
  - 11 method, you selected one that would depend on
  - 12 whether your analyst in your lab accurately picked
  - 13 the right color for the analysis, right?
  - 14 That's just like every lab.
  - 15 Okay. And that then, if you're an
  - 16 analyst and, again, that means that an analyst, and
  - 17 let's just -- has the ability, and I know we
  - 18 disagree about whether this happened, but because of
  - 19 the method you chose, the analyst has the ability to
  - 20 change the results by picking a different color than
  - 21 is observed under the microscope, right?
  - 22 Any PLM analyst who wants to change
  - 23 the colors could do that. We don't do that. And we
  - 24 verified that by looking at chrysotile that was in
  - 25 the same size range and gave the same, same ranges

Page 290

Page 288

**Document 33015-8** 

PageID: 222178

- 1 of color. So, we validated what we were looking at
- 2 and, you know, I'm not -- and I'm not blind from
- 3 the, you know, the criticism of everything here
- 4 because it's outside the norm.
- Okay. And just again, so we
- 6 understand what we mean about why color is
- 7 important, why color is critical to this analysis,
- 8 let's go back to slide 142.
- So, the way this analysis works is
- 10 you're trying to eventually get to a refractive
- 11 index number or two numbers actually in parallel and
- 12 perpendicular. And that's when you're going to do
- 13 your calculation based on those numbers to see what
- 14 the birefringence value is, right?
- 15 A. Correct.
- Q. And what refractive index number you 16
- 17 have is driven by what color the analyst says they
- 18 are seeing, correct?
- A. Yes, sir. As we went over this
- 20 yesterday, I agreed with you.
- 21 So, if you see a particle that is
- 22 actually yellow, it will have a different refractive
- 23 index number than a particle that is purple, right?
- 24 A. That is correct. If it -- if it is
- 25 that purple.

- Page 289
- And so, for example, we went through 1 2 these images, slide 51, that we were not able to see
- 3 yesterday but this particle, as we discussed when I
- 4 just showed you a plain image of it, you told me it
- 5 was golden brown, right?
- That's the main -- that's the main 6 A.
- 7 color there.
- And yet by reversing the process,
- 9 because you actually give -- you see in the black
- 10 box down there, it says "RI 1564," right?
- A.
- 12 O. So, we were able to reverse the
- 13 process to go from that RI to figure out what color
- 14 your analyst was calling this, what color your
- 15 analyst said they were seeing, and that is dark
- 16 purple, right?
- 17 A. You do have that in there but as I've
- 18 talked about yesterday, you don't get these really
- 19 nice colors. You'll get a mixture of them and it's
- 20 just over a process. So, that is one sample. But I
- 21 stick to what it is. That is chrysotile and I rely
- 22 on the analyst and I don't have a problem with that.
- And this particle that you're calling
- 24 purple chrysotile is essentially the same color as
- 25 all the talc plates that we see in the upper left of

- 1 the image, right?
- 2 No. If you look at the ends, you
- 3 know, one point, and you've got darker material
- 4 there, I can see -- I'd have to be on the microscope
- 5 but I can see some purple there. We have a mixture.
- 6 So that's what they chose. You know, we can argue
- 7 about this all day long but if you turn it -- you
- 8 know, that's what we called it and I stick by it.
- You stick by it, but slide 143, just
- 10 to understand how this matters again, the number
- 11 that goes into that calculation, so, all of the
- 12 number on the right, and last time I had this text
- 13 in purple, but, because the number that goes into
- 14 your birefringence calculation, the number that
- 15 you're subtracting the number from, that is based on
- 16 the analyst calling the particle purple; if it was
- 17 yellow, a different number would be there, right?
- 18 Okay. Can we go back to the other A.
- 19 one?
- 20 Q. Sure. 1 -- sorry, 54 -- 51, sorry.
- 21 1.564, that corresponds to purple. If it was, for
- 22 example, a yellow, then you would be in the range --
- 23 in the yellow ranges. You'd have numbers like
- 24 1.579, 1.583, depending on how bright that is, and
- 25 we've talking about the brightness for illumination
  - Page 291

- 1 ranges.
- 2 So, that's not yellow at all. I A.
- 3 appreciate that's what you see.
- Say, we go down to, and we take
- 5 purple -- you would have something in the range of
- 6 about 1.576, 1.576 and 1.561 -- that's a 5100. You
- 7 are still in the range of what is accepted for
- 8 chrysotile.
- 9 Q. Okay.
- 10 A. So, if I --
- Q. 11 According to you.
- 12 A. If I buy your evaluation here and
- 13 that is not the yellows that you're pointing out
- 14 there and I put in a .1576, I am still in the range
- 15 and that is not talc.
- 16 Q. Um-hum.
  - A. What you have in that right-hand
- 18 corner is talc. See that bright up there? Well,
- 19 that we're going to be down in the 420 to 410 range.
- 20 So, it's not talc.
- 21 Dr. Longo, so, let's assume -- see
- 22 these rounded objects. Let's on the right instead.
- 23 Okay? There's one little rounded blue and there's
- 24 some rounded objects up there. Those are talc
- 25 plates, right?

17

